BRISTOL-MYERS SQUIBB COMPANY Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $518.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-11
- BRISTOL-MYERS SQUIBB COMPANY right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $518.00M, a 2254.55% increase from fiscal 2024.
- BRISTOL-MYERS SQUIBB COMPANY right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $22.00M, a 94.34% decline from fiscal 2023.
- BRISTOL-MYERS SQUIBB COMPANY right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $389.00M, a 20.93% decline from fiscal 2022.
- BRISTOL-MYERS SQUIBB COMPANY right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $492.00M, a 115.79% increase from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|
| 2025-12-31 | $518.00M 10-K · filed 2026-02-11 |
| 2024-12-31 | $22.00M 10-K · filed 2025-02-12 |
| 2023-12-31 | $389.00M 10-K · filed 2024-02-13 |
| 2022-12-31 | $492.00M 10-K · filed 2023-02-14 |
| 2021-12-31 | $228.00M 10-K · filed 2022-02-09 |
| 2020-12-31 | $326.00M 10-K · filed 2021-02-10 |
| 2019-12-31 | $231.00M 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |